The microphthalmia-associated transcription factor (MITF) is the ''master melanocyte transcription factor'' with a complex role in melanoma. MITF protein levels vary between and within clinical specimens, and amplifications and gain-and loss-of-function mutations have been identified in melanoma. How MITF functions in melanoma development and the effects of targeting MITF in vivo are unknown because MITF levels have not been directly tested in a genetic animal model. Here, we use a temperature-sensitive mitf zebrafish mutant to conditionally control endogenous MITF activity. We show that low levels of endogenous MITF activity are oncogenic with BRAF V600E to promote melanoma that reflects the pathology of the human disease. Remarkably, abrogating MITF activity in BRAF V600E mitf melanoma leads to dramatic tumor regression marked by melanophage infiltration and increased apoptosis. These studies are significant because they show that targeting MITF activity is a potent antitumor mechanism, but also show that caution is required because low levels of wild-type MITF activity are oncogenic.
INTRODUCTION
Driver genes that stimulate proliferation and survival are important drug targets in cancer. The discovery of BRAF V600E mutations in nevi and melanoma has directly led to the development of small-molecule inhibitors with clear clinical benefit (Flaherty et al., 2012) . Despite these dramatic improvements, drug resistance remains a critical problem, and most patients with metastatic melanoma eventually succumb to the disease within a year. It is therefore necessary to identify additional therapeutic targets in melanoma that can be used in combination with available treatments (Tsao et al., 2012) .
One of the important genes in melanocyte development and melanoma is the highly conserved ''master melanocyte transcription factor'' microphthalmia-associated transcription factor (MITF) (Levy et al., 2006) . MITF responds to multiple signaling cascades to orchestrate genes involved in melanocyte growth, differentiation, and survival . Although MITF mutations in development lead to similar phenotypes across species, the function of MITF in melanoma is complex and not fully understood. MITF is expressed in most melanomas, although MITF protein levels vary between melanoma specimens, with some subsets of melanoma showing high levels and others showing low levels of MITF (Flaherty et al., 2012) . MITF activity can also vary within an individual melanoma, such that low levels of MITF promote invasion and stem-cell like phenotypes and moderate levels of MITF activity promote cell cycle progression (Goodall et al., 2008; Hoek and Goding, 2010; Cheli et al., 2011; Strub et al., 2011; Cheli et al., 2012) . The ability of MITF to activate cancer hallmark genes makes it an important mediator of oncogenic signaling in cancer. This is underscored by evidence that MITF is at least partially responsible for the oncogenic potential of BRAF in cells (Wellbrock and Marais, 2005; Wellbrock et al., 2008) . Studies from melanoma cells indicate that a key function of BRAF V600E seems to be to maintain MITF activity at a critical threshold where it promotes proliferation, invasion, and survival, without promoting differentiation (at higher levels) or apoptosis or senescence (at lower levels) (Giuliano et al., 2010; Hoek and Goding, 2010; Cheli et al., 2011; Strub et al., 2011; Cheli et al., 2012) However, MITF may have additional cooperating functions in melanoma. MITF is amplified in some melanomas, and expression of ectopic MITF can cooperate with BRAF V600E to transform primary human melanocytes and neural crest cells (Garraway et al., 2005; Kumar et al., 2013) . In addition, MITF mutations have been identified in BRAF V600E melanomas including somatic mutations with either hypomorphic or increased activity (Cronin et al., 2009) , and a germline SUMOylation E318K mutation that is a melanoma risk factor and confers differential gene expression of MITF target genes (Bertolotto et al., 2011; Yokoyama et al., 2011) . Thus, MITF is important in melanoma because it is an effector of oncogenic signaling, and also because it may have additional activity that contributes to melanomagenesis.
How MITF activity contributes to melanoma development and survival in an animal is unknown. Animal models are fundamental in establishing how genetic mutations contribute to cancer in vivo. Although many Mitf mutant mouse lines exist (Hou and Pavan, 2008) , they do not permit conditional control of MITF activity in melanoma development or survival. Here, we address the importance of MITF activity in melanoma in vivo using a conditional mitfa temperaturesensitive zebrafish mutant (mitfa vc7 ) in which endogenous MITF activity can be altered by changing the temperature of the water (Johnson et al., 2011; Taylor et al., 2011) . In zebrafish, there are two mitf genes (mitfa and mitfb), and mitfa is essential for the development of neural crest-derived melanocytes (Lister et al., 1999) . Thus, by using a mitfa mutant we specifically control endogenous MITF activity in skin melanocytes, and avoid the potential complication of MITF activity in other tissues, such as those described in mouse mutants (Hou and Pavan, 2008) . We show that low levels of wild-type MITF activity are oncogenic with BRAF V600E to promote melanoma in vivo, and that abrogating MITF activity in melanoma leads to rapid tumor regression. These results reveal that critical thresholds of MITF lead to dramatically different melanoma outcomes, and indicate that although targeting MITF activity is a potent antitumor approach, simply reducing MITF activity is sufficient to drive melanoma in BRAF V600E melanocytes.
RESULTS

Hypomorphic MITF is oncogenic with BRAF V600E in melanomagenesis
We sought to test whether hypomorphic levels of MITF activity could contribute to melanoma development in vivo using a zebrafish mitf temperature-sensitive mutant, mitfa vc7 (Figure 1a-d ; Johnson et al., 2011 ; originally characterized as fh53) and a transgenic line expressing BRAF V600E in melanocytes that we have previously developed and has been effective in the identification of cooperating driver genes ( Figure 1e ) (Patton et al., 2005; Ceol et al., 2011) . The mitfa vc7 allele is a splice site mutation at the intron 6 splice donor site that leads to a reduction in melanocytes when zebrafish are reared at o26 1C, and an almost complete loss of melanocytes at 428 1C (Figure 1b-d) (Johnson et al., 2011 (Figure 1f) . Importantly, at o26 1C, BRAF V600E mitf zebrafish developed nevi (Figure 1g ), some of which progressed to melanoma (n ¼ 18/67; Figure 1h -j). The mitfa vc7 allele is a splice site mutation, and we confirmed that the BRAF V600E mitf melanomas expressed the mis-spliced þ intron6 variant with hypomorphic levels of correctly spliced mitfa ( Figure 1k p53) zebrafish, and found that the incidence was similar between the two genotypes (n ¼ 48/177; Figure 1j ). These results show that hypomorphic levels of MITF activity interact genetically with BRAF V600E to promote melanoma in vivo.
BRAF V600E
mitf melanomas display characteristic histopathological features
We wanted to know whether the mitf and p53 cooperating mutations contributed to melanoma pathology. We found that most BRAF V600E mitf melanomas displayed a superficial spreading growth pattern with some invasion into the underlying muscle (Figure 2a ; n ¼ 22/26). This pattern was reminiscent of superficial spreading melanoma, the most common subtype of human melanoma. A striking characteristic feature of BRAF V600E mitf melanomas was the presence of large, heavily pigmented cells throughout the tumor (n ¼ 26/26), and often found in the kidney (the site of the hematopoietic compartment in zebrafish). Macrophages laden with melanin (melanophages) are often a feature of human malignant melanoma, and express CD68. We found these large cells to correspond to CD68-positive cells in the BRAF (Figure 2f and g ). These results show that there is a strong genotype-phenotype correlation for cooperating mutations that can directly affect growth features and cellular histology.
Differential MITF target gene expression between melanoma genotypes
We wanted to understand how hypomorphic MITF activity contributed to melanoma, and hypothesized that MITF target genes may be differentially expressed between the melanoma genotypes. We performed quantitative real-time PCR on MITF target genes involved in proliferation (cdk2), cell cycle arrest (p16, p21), differentiation (tyr, dct), and survival (bcl-2, hif1a, c-met) (Figure 3 ). Despite the differences in phospho-histone H3 staining between the genotypes, the differences in cdk2, p16, and p21 cycle threshold (Ct) values between melanoma genotypes were not statistically significant (Figure 3a-c) . Neither was there a significant difference in the cycle threshold values for expression of p53, bcl-2, or hif1a between melanoma genotypes (Figure 3f-h ). These results indicate that despite the reduced levels of MITF activity in BRAF V600E mitf melanomas, there is sufficient MITF activity to control MITF target genes involved in cell proliferation and survival. Strikingly, BRAF V600E mitf melanomas expressed lower levels of differentiation genes (tyr and dct), as indicated by higher cycle threshold values (Figure 3d and e) . Unexpectedly, we found that BRAF V600E mitf melanomas expressed significantly higher levels of c-met compared with BRAF V600E p53 melanoma (Figure 3i ). c-met is a MITF target gene, but is also transcriptionally regulated by Pax3 in melanoblasts and melanomas (McGill et al., 2006; Beuret et al., 2007; Mascarenhas et al., 2010) . The tumor-initiating potential of cell types can vary within a lineage and differing tumor potentials may exist within the melanocyte lineage (Kumar et al., 2013) . Although the tumors are heterogeneous, the low expression of differentiation genes (tyr and dct) coupled with high c-met gene expression pattern suggests that hypomorphic MITF activity may maintain melanocytes in a less differentiated state that is more susceptible to BRAF V600E transformation.
Loss of MITF causes melanoma regression
MITF is a lineage survival oncogene in cells, but the effect of abrogating MITF activity in an animal model of melanoma in vivo is unknown. To develop an animal system that could directly validate MITF as a drug target, we tested the effects of dramatically reducing MITF activity on melanoma survival by increasing the water temperature to the restrictive conditions (32 1C); none of the aberrant mitfa vc7 splice products are sufficient for melanocyte development at these restrictive temperatures (Johnson et al., 2011) , and MITF activity is not required to maintain the activity of the mitfa promoter fragment driving the BRAF V600E transgene (Supplementary Figure S2 online; Dooley et al., 2013) . BRAF V600E mitf vc7 zebrafish were reared at o26 1C to promote melanoma development, and then the temperature of the water was raised to 32 1C to turn off MITF activity. Within 2 weeks, 8/12 melanomas had dramatically regressed (Figure 4a ; fish 1 and 2 mutation and not just the water temperature because BRAF-V600E p53 zebrafish upshifted to 32 1C for 2 weeks showed no tumor regression and even continued growth (n ¼ 6/6; Figure 4b ). By 2 months, 12/15 very large tumors showed regression, and 6 of these fish showed complete regression and even healing at the tumor site (Figure 4c ; fish 3 and 4). Interestingly, despite the striking levels of melanoma regression, melanomas recurred following a temperature shift to o26 1C, indicating that a subpopulation of melanoma cells with very low MITF activity survive and are capable of repopulating the tumor site (Supplementary Figure S3 online) .
To understand the process of melanoma regression, we shifted BRAF V600E mitf zebrafish to the restrictive temperature (32 1C) for 7 days to analyze melanoma regression in progress. Histological analysis of the regressing melanomas showed evidence of tumor regression, characterized by marked loss of tumor cell density and accumulation of heavily pigmented melanophages (n ¼ 7/7; Figure 5a and apoptosis contributed to regression, we stained sections of the regressing BRAF V600E mitf melanomas with antibodies to detect active (cleaved) Caspase-3. We found high levels of active Caspase-3 in the regressing tumors compared with BRAF V600E-mitf melanomas at o26 1C (n ¼ 5 in each group; Figure 5c ). We conclude that there is a genetic dependency on MITF activity in BRAF V600E mitf melanoma.
DISCUSSION
Identifying BRAF
V600E cooperating mutations that drive melanoma progression is critical for developing new therapeutic approaches and tackling drug resistance. Accumulating evidence indicates that MITF activity is a key contributing factor in melanoma (Tsao et al., 2012) . We now show in an animal that a low level of wild-type MITF activity is oncogenic with BRAF V600E and that abrogating MITF activity in melanoma leads to tumor regression.
The BRAF V600E mitf model is relevant to human melanoma, because for some patients, low expression of MITF is associated with disease progression and poor prognosis (Salti et al., 2000; Levy et al., 2006) . In these contexts, exogenous expression of MITF leads to inhibition of proliferation (Selzer et al., 2002; Wellbrock and Marais, 2005) . This is in apparent contrast to evidence that MITF amplification is also an indicator of poor prognosis, and that MITF cooperates with BRAF V600E to transform melanocytes (Garraway et al., 2005) .
These differences in MITF activity may reflect distinct subtypes of melanoma; however, another possibility is that MITF amplification indicates the need for melanoma cells to maintain sufficient MITF activity for survival in the context of high BRAF V600E signaling (Garraway et al., 2005; Wellbrock et al., 2008) . Thus, a common feature of melanoma may involve maintaining sufficient MITF activity for survival and proliferation while at the same time restricting higher levels of MITF activity that promote cell cycle arrest and differentiation or lower levels that lead to cell cycle arrest and apoptosis (Gray-Schopfer et al., 2007; Hoek and Goding, 2010) . Here, the temperature-sensitive nature of the zebrafish mitfa vc7 mutant allele enables MITF activity to be varied within an individual animal by altering the water temperature, thereby revealing the role of MITF activity levels in melanomagenesis and survival in vivo, although we cannot exclude the possibility that the mitfa vc7 mutant has additional functions that contribute to melanoma.
Histopathological characteristics of melanoma are determined by a number of factors, and at least some are genetically determined (Whiteman et al., 2011) . This is illustrated by the clinical classification of BRAF V600E melanomas as a subgroup based on histomorphological features (Viros et al., 2008) . We show here that cooperating mutations also have an important role in determining the pathological features of melanoma. We find that low, oncogenic levels of MITF activity contribute to melanoma pathology, possibly by maintaining melanoma cells in a progenitor-like state. Notably, macrophages laden with melanin (melanophages) were a diagnostic feature of the BRAF V600E mitf melanomas. Melanophages are found in human melanomas, are indicative of an immune response, and predict an improved prognosis for patients, possibly because of tumor regression through macrophage engulfment of melanoma cells (Handerson et al., 2007) . Thus, BRAF V600E cooperating mutations can directly influence tumor morphology, as well as tumor-immune cell interactions.
The dramatic recurrence of melanomas in patients following treatment with the BRAF V600E inhibitor, vemurafenib, indicates that combination therapies that target multiple pathways in melanoma may be necessary to improve patient outcome. MITF activity has been implicated as an important drug target (Flaherty et al., 2012; Tsao et al., 2012) , and we now show that shutting off endogenous MITF activity in vivo leads to dramatic and rapid melanoma regression, characterized by melanophage infiltration and apoptosis. The melanomas recur at the same location following reactivation of MITF activity (Supplementary Figure S3 online) , although at this stage we cannot distinguish whether this reflects incomplete tumor regression or a cancer-initiating population that can survive with low-to-no MITF activity. Notably, although melanophages are presumably participating in melanoma regression and/or clearance ( Figure 5 ), we do not know their function in melanoma growth (Figure 2a ): macrophages can lead to both melanoma regression (Nakashima et al., 2012) and promotion (Zaidi et al., 2011) , or form melanoma-macrophage hybrids (Pawelek, 2007) .
In conclusion, our zebrafish model provides in vivo genetic evidence that targeting MITF activity-either directly or through regulators of MITF-may be an effective approach to melanoma therapy. Critically, our studies show that although targeting MITF activity is a potent antitumor mechanism, it must be done with caution because partial or ineffective targeting of MITF is oncogenic.
MATERIALS AND METHODS
All zebrafish work was done in accordance with the United Kingdom Home Office Animals (Scientific Procedures) Act (1986) 
Histopathology
Adult zebrafish were prepared for histopathology as described previously (Patton et al., 2011) . Antibodies and antigen retrieval methods were as follows: anti-phospho-extracellular signal-regulated kinase 1/2, 1:1,000, EDTA buffer (Cell Signaling Technology, Danvers, MA); p53 5.1, 1:500, citrate buffer; phospho-histone H3, 1:1,000, citrate buffer (Cell Signaling Technology); Melan-A, 1:75, citrate buffer (DAKO, Cambridge, UK). For the proliferation analysis, the total melanoma cell population in each of the six images was counted (between 1,000 and 3,000 cells) and the percentage of phospho-histone H3-stained cells calculated.
PCR analysis
Total RNA was isolated using TRIzol reagent (Invitrogen, Paisley, UK). First-strand complementary DNA was synthesized from 1 mg of total RNA in a 10 ml reaction using SuperScript III Reverse Transcriptase (Invitrogen). Complementary DNA was then amplified by PCR using primers covering the alternative splicing region in the mitfa vc7 gene.
Quantitative real-time PCR was performed using SYBR Green Jumpstart Taq Readymix for high-throughput real-time PCR (Sigma, St Louis, MO). Reactions were run in an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Paisley, UK) using the SYBR Green protocol. The zebrafish b-actin gene was used as reference. Primers sequences are presented in Supplementary  Table S1 online. 
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